ES2010527A6 - Procedimiento para preparar un nuevo fenilcarbamato con actividad anticolinesterasis. - Google Patents

Procedimiento para preparar un nuevo fenilcarbamato con actividad anticolinesterasis.

Info

Publication number
ES2010527A6
ES2010527A6 ES8800651A ES8800651A ES2010527A6 ES 2010527 A6 ES2010527 A6 ES 2010527A6 ES 8800651 A ES8800651 A ES 8800651A ES 8800651 A ES8800651 A ES 8800651A ES 2010527 A6 ES2010527 A6 ES 2010527A6
Authority
ES
Spain
Prior art keywords
phenyl carbamate
ethyl
phenylncarbamate
dimethylamino
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8800651A
Other languages
English (en)
Inventor
Albert Enz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2010527(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES2010527A6 publication Critical patent/ES2010527A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

PROCEDIMIENTO PARA PREPARAR UN NUEVO FENILCARBAMATO CON ACTIVIDAD ANTICOLINESTERASIS, DE FORMULA (I). COMPRENDE SEPARAR EL ENANTIOMERO DE RACEMATO CORRESPONDIENTE, POR REACCION CON ACIDO DI-0,0''-P-TOLUIL-TARTARICO. EL COMPUESTO (I), EN FORMA DE BASE LIBRE O EN FORMA DE SAL DE ADICION DE ACIDO, TIENE UTILIDAD COMO FARMACO, EN PARTICULAR PARA LA ADMINISTRACION TRANSDERMICA SISTEMICA.
ES8800651A 1987-03-04 1988-03-04 Procedimiento para preparar un nuevo fenilcarbamato con actividad anticolinesterasis. Expired ES2010527A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
ES2010527A6 true ES2010527A6 (es) 1989-11-16

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8800651A Expired ES2010527A6 (es) 1987-03-04 1988-03-04 Procedimiento para preparar un nuevo fenilcarbamato con actividad anticolinesterasis.

Country Status (29)

Country Link
US (1) US5602176A (es)
JP (3) JP2625478B2 (es)
KR (1) KR0133686B1 (es)
AT (1) AT394190B (es)
AU (1) AU618949B2 (es)
BE (1) BE1001467A3 (es)
CA (1) CA1307003C (es)
CH (1) CH675720A5 (es)
CS (1) CS411091A3 (es)
CY (1) CY1735A (es)
DK (1) DK175762B1 (es)
ES (1) ES2010527A6 (es)
FI (1) FI89165C (es)
FR (1) FR2611707B1 (es)
GB (1) GB2203040C (es)
GR (1) GR1000023B (es)
HK (1) HK110093A (es)
HU (1) HU201906B (es)
IE (1) IE61714B1 (es)
IL (1) IL85609A (es)
IT (1) IT1219853B (es)
LU (2) LU87150A1 (es)
MY (1) MY103225A (es)
NL (1) NL195004C (es)
NZ (1) NZ223714A (es)
PT (1) PT86875B (es)
SA (1) SA93140384B1 (es)
SE (1) SE8800731L (es)
ZA (1) ZA881584B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
EP0755685A4 (en) * 1994-04-15 2000-05-03 Meiji Seika Kaisha PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DK0966435T3 (da) 1996-12-18 2005-08-15 Teva Pharma Aminoindanderivater
JP4116085B2 (ja) * 1996-12-18 2008-07-09 テバ・ファーマシューティカル・インダストリーズ・リミテッド フェニルエチルアミン誘導体
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
IL141762A0 (en) 1998-10-01 2002-03-10 Novartis Ag New oral formulations
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
JP2002531502A (ja) * 1998-12-11 2002-09-24 デイビス、ボニー 視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
MXPA04006900A (es) * 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
CN1898201A (zh) * 2003-10-21 2007-01-17 森蒂有限公司 可抑制胆碱酯酶和释放药理学活性试剂的氨基甲酸酯
GB2409453A (en) 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja) 2005-09-15 2013-01-09 株式会社ソニー・コンピュータエンタテインメント 強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
ES2632638T3 (es) * 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
US8101782B2 (en) * 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
AU2008276459A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US8324429B2 (en) * 2008-01-10 2012-12-04 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
BR112012017168B1 (pt) 2009-12-22 2022-03-15 Luye Pharma Ag Sistemas terapêuticos transdérmicos, seu processo de preparação, e usos de um polímero ou copolímero
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
SG10201505374TA (en) 2010-03-29 2015-08-28 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
ES2545094T3 (es) 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
JP6017543B2 (ja) 2011-05-20 2016-11-02 エスケー ケミカルズ カンパニー, リミテッドSk Chemicals Co., Ltd. リバスティグミン含有パッチ
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
EP2752188B1 (en) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.

Also Published As

Publication number Publication date
US5602176A (en) 1997-02-11
CH675720A5 (es) 1990-10-31
IL85609A0 (en) 1988-08-31
GB2203040C (en) 2014-07-30
KR880011088A (ko) 1988-10-26
SE8800731A0 (sv) 1988-09-05
NL195004C (nl) 2003-11-04
IT1219853B (it) 1990-05-24
JP2625478B2 (ja) 1997-07-02
FR2611707B1 (fr) 1990-04-20
PT86875A (pt) 1988-04-01
HU201906B (en) 1991-01-28
KR0133686B1 (ko) 1998-04-21
NL195004B (nl) 2003-07-01
NL8800436A (nl) 1988-10-03
IE61714B1 (en) 1994-11-30
IT8847693A0 (it) 1988-03-04
AU1255488A (en) 1988-09-08
HK110093A (en) 1993-10-29
JPH09165362A (ja) 1997-06-24
JP2859225B2 (ja) 1999-02-17
FI880972A (fi) 1988-09-05
LU87150A1 (fr) 1988-11-17
DK112588D0 (da) 1988-03-02
JPS63238054A (ja) 1988-10-04
HUT49325A (en) 1989-09-28
GB2203040B (en) 1990-10-24
FI880972A0 (fi) 1988-03-02
BE1001467A3 (fr) 1989-11-07
DK175762B1 (da) 2005-02-14
CY1735A (en) 1994-06-03
ZA881584B (en) 1989-11-29
CA1307003C (en) 1992-09-01
SE8800731L (sv) 1988-09-05
SA93140384B1 (ar) 2006-04-04
CS411091A3 (en) 1992-12-16
IE880583L (en) 1988-09-04
FR2611707A1 (fr) 1988-09-09
ATA55188A (de) 1991-08-15
NZ223714A (en) 1994-05-26
MY103225A (en) 1993-05-29
SE8800731D0 (sv) 1988-03-02
GB2203040A (en) 1988-10-12
GB8804888D0 (en) 1988-03-30
IL85609A (en) 1992-07-15
PT86875B (pt) 1992-05-29
FI89165C (fi) 1993-08-25
GR880100125A (en) 1989-01-31
AU618949B2 (en) 1992-01-16
GR1000023B (el) 1990-01-31
FI89165B (fi) 1993-05-14
DK112588A (da) 1988-09-05
JPH09118617A (ja) 1997-05-06
AT394190B (de) 1992-02-10
LU90297I2 (fr) 1998-12-07

Similar Documents

Publication Publication Date Title
ES2010527A6 (es) Procedimiento para preparar un nuevo fenilcarbamato con actividad anticolinesterasis.
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
IL74497A0 (en) Pharmaceutical compositions and phenyl carbamate derivatives
NL300084I1 (nl) Nieuwe thiofeencarbonzuur-esters van aminoalkoholen, hun kwaternairiseringsprodukten, alsmede de bereiding en toepassing van deze verbindingen.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
IL86782A0 (en) Amino acid derivatives,processes for the preparation thereof and pharmaceutical compositions comprising the same
SE7602317L (sv) 1,4-dihydropyridinkarbonsyraalkylestrar till anvendning som lekemedel och sett att framstella desamma
JO1502B1 (en) New pharmacy vehicles
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
DK0460062T3 (da) Huperzin A-analoger
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
ES2037095T3 (es) Un procedimiento para preparar una composicion farmaceutica.
IT8722501A0 (it) Formulazioni farmaceutiche per somministrazione transdermica.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
DK513188A (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
IL77009A0 (en) Biphenylyloxy and biphenylylalkoxy aryl acyl urea derivatives,processes for the preparation thereof and pesticidal compositions containing the same
PT83253A (en) Process for preparing p-acylaminobenzamides
CA976970A (en) N-((diamino, 2&#39;,4&#39; aza 3&#39;) phenyl)-benzoquinones imines
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
DE3864841D1 (de) Carbonsaeure-derivate.
ATE36957T1 (de) N,n-diethyl-5-methyl-2h,1-benzothiopyrano-(4,3, - cd)-indazol-2-ethanamine, diese enthaltende zubereitungen und ihre verwendung.
GB1420976A (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
GR3005495T3 (es)
SE8704049D0 (sv) Novel pharmacological compounds
FR2567755B1 (fr) Nouveau medicament anti-tumoral contenant comme ingredient actif le triacetoxy-1,8,9 anthracene

Legal Events

Date Code Title Description
PC1A Transfer granted
SPCF Request for supplementary protection certificate filed

Free format text: RIVASTIGMINA (EXELON)

Spc suppl protection certif: C9800031

Filing date: 19981022

SPCG Supplementary protection certificate granted

Free format text: RIVASTIGMINA (EXELON)

Spc suppl protection certif: C9800031

Filing date: 19981022

Expiry date: 20130304

Effective date: 20010927

FD1A Patent lapsed

Effective date: 20100528